Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on…
<!-- Name:DistributionId Value:8795293 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Browsing Tag
$ALIM
Alimera Announces Agreement with Jaeb Center for Health Research on Behalf of the…
ATLANTA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians…
Alimera Announces Reimbursement of Uveitis Indication Granted for ILUVIEN® in Ireland
ATLANTA, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians,…
Alimera Announces Approval and Pricing Granted for ILUVIEN® for Uveitis in Italy
ATLANTA, July 08, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and…